ArticleBMC veterinary research2026
Development and immunological evaluation of a ferritin nanoparticle vaccine displaying chicken infectious anemia virus VP1-VP2 proteins.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChicken infectious anemia virus (CIAV) causes immunosuppression, aplastic anemia, and lymphoid atrophy in young chicks, causing major economic losses to the poultry industry. Vaccination is the primary strategy for disease control. This study aimed to develop a ferritin-based nanoparticle vaccine displaying CIAV VP1-VP2 proteins and evaluate its protective efficacy in chicks.
resultsUsing the SpyTag003/SpyCatcher003 system, we expressed ferritin-SpyCatcher003 (SC-FN) in insect cells and SpyTag003-VP2-VP1Nd129 in E. coli, achieving in vitro assembly of FN-VP2-VP1Nd129 nanoparticles, which were confirmed by SDS-PAGE, Western blotting, and transmission electron microscopy. Two-week-old chicks immunized with the nanoparticle vaccine developed significantly higher CIAV-specific antibody levels compared to the control group. Following lethal challenge with CIAV Cux-1 strain, the vaccine group showed significantly higher hematocrit values and thymus indices (p < 0.001), and importantly, no viral nucleic acid was detected in their thymus tissues.
conclusionsWe successfully constructed a ferritin nanoparticle-based antigen display system for CIAV. The vaccine induced robust humoral immunity, effectively protected against viral replication and clinical disease, and offers a promising new strategy for developing safe and effective subunit vaccines against CIAV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.